CADL vs CBRE · $592.0M cap vs P/E 43, rev $40.55B
Candel Therapeutics Inc (CADL) versus CBRE Group Inc Class A (CBRE) — a side-by-side from cached financials, not a winner call.
Candel Therapeutics Inc (CADL) is a biotechnology company listed on NASDAQ.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
CADL does not have a complete income-statement cache yet.
Latest reported CBRE revenue for 2025-12-31 was $40.55B. Net income was $1.16B. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
CADL currently screens at market cap $592.0M. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Not investment advice. Open the CADL and CBRE stock pages for the full models.
Not investment advice.